Global Market Study on Urothelial Carcinoma Diagnostics: Discovery of Novel Biomarkers Fuelling Demand


Urothelial Carcinoma Diagnostics  Market
  • Published On : Sep-2020 |
  • Pages : 245 Pages |
  • Format : Urothelial Carcinoma Diagnostics  Market Urothelial Carcinoma Diagnostics  Market Urothelial Carcinoma Diagnostics  Market Urothelial Carcinoma Diagnostics  Market

Increased knowledge about specific cancer biomarkers is fuelling revenue opportunities for diagnostic companies that aid in the treatment of various cancer patients through improvement in detection (both, accuracy and time spent). Technological advancements in the field of biotechnology have enhanced the identification of potential cancer biomarkers, and some of the recent diagnostics adopted for detection and disease progression of urothelial carcinoma include the Immuno-Histochemical assay test, In Situ hybridization test, biopsy, and cystoscopy. Some of the specialty biomarker tests for urothelial carcinoma diagnostics are UroVysion, ImmunoCyt/uCyt+, bladder tumor antigen, CxBladder, NMP-22, and Xpert Bladder Cancer.

As such, the global urothelial carcinoma diagnostics market is set for threefold growth over the next ten years (2020 to 2030).

Urothelial Carcinoma Diagnostics Market Trends

Higher Mortality Rate Associated with Urothelial Carcinoma to Create Awareness about Early Urothelial Carcinoma Screening: Every year, 3.8 Mn new cases of urothelial carcinoma occur around the world, with an estimated 15 thousand deaths from this disease. However, the recurrence rate of cancer is nearly 30-50%, and accounts for the most mortalities.

The fairly high mortality rate interrelated with urothelial carcinoma can be elucidated by late diagnosis with a high propensity for metastasis. If identified at a primary stage, the benign tumor can be eradicated definitively by surgical interlineation, but the metastatic disease spread has a poor diagnosis of urothelial carcinoma, with an estimated average survival of 6-8 months. The higher risk of developing urothelial carcinoma from benign lesions is directly fuelling the demand for advanced diagnostic tests for urothelial carcinoma, and, as such, will expand the urothelial carcinoma diagnostics market size substantially through 2030.

Increasing Need for Preventive Treatment to Boost Demand for Early Diagnostics: The World Health Organization (WHO) estimates in its World Cancer Report that worldwide cases of cancer will ascend from 14.1 Mn new cases in 2012 to 25 Mn new cases per year over the next 20 years. Increased demand for treatment of urothelial carcinoma is a key driver for increasing the revenue inflow from diagnostic tests and procedures.

Moreover, early detection by use of modern diagnostics enables quick medical decision-making and consequent treatment. Patient life years gained suffices the justification of even costlier urothelial carcinoma diagnostics, and thus, provides even better revenue outlook.

Increasing Prevalence of Cancer to Surge Demand for Urothelial Carcinoma Diagnostics: Increasing biomedical research using molecular diagnostics is expected to create a conducive atmosphere for the growth of the urothelial carcinoma diagnostics market in the near future. Recently, a clinical oncology molecular diagnostic test has been applied for the development of immunotherapies cancer and biomarkers. Therefore, increasing prevalence of urothelial carcinoma is expected to drive the growth of the urothelial carcinoma diagnostics market.

In recent years, there has been considerable interest in clinical molecular diagnostics for urothelial carcinoma. Therefore, various clinical development programs in several countries are aimed at increasing urothelial carcinoma screening programs with the help of governments. This results in early diagnostics and screening of urothelial carcinoma in patients.

Moreover, leading players are forming diagnostic companions in various regions with a high prevalence rate to gain maximum market share and expand their footprints in untapped market. For instance, in March, 2020, Thermo Fisher Scientific signed an agreement with Janssen to co-develop companion diagnostics for cancer. In August, 2020 Thermo Fisher Scientific signed a companion diagnostic agreement with Hengrui Therapeutics, Inc.

Regional Outlook of Urothelial Carcinoma Diagnostics Market

North America currently holds more than 36% of the global urothelial carcinoma diagnostics market share. High prevalence of urothelial carcinoma is increasing the demand for cancer diagnostics in this region. However, the market in East Asia and South Asia will experience significant growth over the forecast period, owing to factors such as increasing burden of urothelial carcinoma and a large population base. Increased R&D investments, improving healthcare facilities, and more government initiatives are expected to further support the growth of the urothelial carcinoma diagnostics market in these regions.

COVID-19 Crisis Impact on Urothelial Carcinoma Diagnostics Market

The global outbreak of COVID-19 led to shutdowns in the first half of 2020, and all industries faced heavy disruptions, which has also had an unusual impact on the urothelial carcinoma diagnostic market. The pandemic has created a short-term decline in the manufacturing and sales of urothelial carcinoma diagnostic kits. All this has been due to lockdowns, movement restrictions, and suspension of trade activities. The urothelial carcinoma diagnostic market is expected to gradually get back to its normal growth trajectory as the coronavirus outbreak gets contained.

Analysts’ Viewpoint

An immense analysis of the urothelial carcinoma diagnostics market has brought our analysts to a conclusion that, the market is growing at a remarkable pace. Currently, reagent and kits is the most lucrative segment for leading manufacturers, and, as such, this segment dominates the global urothelial carcinoma diagnostics market in term of market growth. Currently, North America holds more than half of the revenue share due to high adoption of urothelial carcinoma diagnostics in the region. Developing countries such as India, Brazil, China, and Thailand are expected to offer lucrative opportunities for the growth of the urothelial carcinoma diagnostics market, owing to increasing awareness and initiatives by local governments for research & development on cancer.

Urothelial Carcinoma Diagnostics Market - Scope of the Report

The latest publication by Persistence Market Research (PMR) on the global urothelial carcinoma diagnostics market evaluates the opportunities and current market landscape, and provides detailed analysis and updates about corresponding sections affecting the global urothelial carcinoma diagnostics market space. The study offers detailed insights on key market dynamics, which include the drivers, restraints, trends, and opportunities in the urothelial carcinoma diagnostics market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2020-2030.

Important indicators for the successful growth of the urothelial carcinoma diagnostics market are presented in this comprehensive report, which include Year-on-Year (Y-o-Y) growth analysis of the market and compounded annual growth rate (CAGR), which are described in an exhaustive way in PMR's research. This research study can support readers to know the demand for urothelial carcinoma diagnostics and quantitative development opportunities during the study period.

The research is beneficial for shareholders in the urothelial carcinoma diagnostics landscape, including market investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the urothelial carcinoma diagnostics market. The insights and wisdom presented in this PMR’s study can be leveraged by shareholders in the urothelial carcinoma diagnostics market, industry experts, investors, researchers, and reporters, as well as urothelial carcinoma diagnostics business enthusiasts.

Market statistics as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the urothelial carcinoma diagnostics market are also included in the current study. Depending on potential developments in the urothelial carcinoma diagnostics market, substantive insights are also encountered in this report. Additionally, by virtue of the data submitted in this market report, minor companies and new entrants in the urothelial carcinoma diagnostics industry can be aided in making suitable company choices to achieve traction in the urothelial carcinoma diagnostics market.

Key Segments of Urothelial Carcinoma Diagnostics Market

PMR’s study on the urothelial carcinoma diagnostics market offers information divided into four important segments— product type, test type, end user, and region. This report offers comprehensive data and information about the important market dynamics, and growth parameters associated with these categories.

Product Type  

  • Reagent and Kits
  • Instruments

Test Type

  • Urinalysis Test
  • Molecular Diagnostic Test
  • Biomarker Test
    • Immuno-Histochemical Assay Test
    • In Situ Hybridization Test
    • Biopsy
    • Cell-Based Test
  • Imaging Test
  • Cytoscopy
  • Ureteroscopy

End User

  • Hospitals
  • Diagnostic Laboratories
  • Research and Academic Institutes
  • Clinical Research Organizations

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

Key Questions Answered in PMR’s Urothelial Carcinoma Diagnostics Market Report

  • Which regions will continue to remain the most profitable regional markets for urothelial carcinoma diagnostics market players?
  • Which factors will induce a change in the demand for urothelial carcinoma diagnostics during the assessment period?
  • How will changing trends impact the urothelial carcinoma diagnostics market?
  • How can market players capture the low-hanging opportunities in the urothelial carcinoma diagnostics market in developed regions?
  • What are the winning strategies of stakeholders in the urothelial carcinoma diagnostics market to upscale their position in this landscape?
  • What are the restraints that investors need to be aware of and might tackle while investing in the urothelial carcinoma diagnostics market?
  • What are the developmental trends in urothelial carcinoma diagnostics sectors that will impact the market?
  • How can businesses in the urothelial carcinoma diagnostics market avail the growth opportunities in developed and emerging sectors?

Urothelial Carcinoma Diagnostics Market: Research Methodology

In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the urothelial carcinoma diagnostics market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the urothelial carcinoma diagnostics market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the urothelial carcinoma diagnostics market, and makes PMR’s projections on the growth prospects of the urothelial carcinoma diagnostics market more accurate and reliable.

Companies covered in Urothelial Carcinoma Diagnostics Market Report

  • GE Healthcare
  • Roche Holding
  • Illumina
  • IDL Biotech
  • Agilent Technologies
  • Olympus Corporation
  • Philips Healthcare
  • Abbott Molecular
  • Bio-Rad Laboratories, Inc
  • Thermo Fisher Scientific, Inc.( Qiagen N.V.)
  • Danaher Corporation (Cepheid)

Urothelial Carcinoma Diagnostics Market

Back To Top